Clinical Trials Logo

Clinical Trial Summary

This research study is being done to study the effects, both good and bad, of calcineurin inhibitors and the drug Cozaar (losartan), on kidney function and kidney scarring following a liver transplant.


Clinical Trial Description

This study is a double-blinded, placebo controlled trial to help determine the pathogenesis of chronic renal dysfunction in patients undergoing liver transplantation. It will examine the renal function and renal morphology in patients on calcineurin inhibitors and the effects of Cozaar (losartan) following liver transplantation. Participants will have blood, urine and iothalamate clearance test, to look at kidney function prior to transplant. At the time of transplant, kidney biopsies will be performed in the operating room under anesthesia. Participants will be in the study for one year. At three weeks following liver transplant, participants will be randomly assigned to receive either a placebo (inactive drug) or the study drug (losartan). The participant will need to continue to return to the clinic at the normal scheduled intervals. During these times blood and urine tests will be done. A kidney biopsy will be performed at the yearly exam and study pills will be stopped. The researchers will continue to follow participant's creatine measurements for the next 10 years. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00275639
Study type Interventional
Source Mayo Clinic
Contact
Status Completed
Phase Phase 4
Start date December 2004
Completion date August 2007

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01525797 - Blood Draw Study for Liver Transplant Patients N/A
Completed NCT00587418 - L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients N/A
Completed NCT01889758 - Pharmacokinetic Studies of Tacrolimus in Transplant Patients Phase 4
Completed NCT02482974 - Conversion From Sirolimus to Everolimus in the Maintenance Treatment of Liver Transplant Recipients N/A
Completed NCT02320422 - Adult Liver Transplant Enhanced Care N/A
Active, not recruiting NCT05077254 - COVID Protection After Transplant-Immunosuppression Reduction Phase 2
Completed NCT01672164 - Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients N/A
Completed NCT01638559 - Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients Phase 2
Recruiting NCT06418893 - Effect of TCI Propofol on Liver Transplant (TCI) Propofol on Intra-operative Usage of Vasopressors in Liver Transplant Recipients. Phase 2/Phase 3